Sodium hyaluronate-g-2-((N-(6-aminohexyl)-4-methoxyphenyl)sulfonamido)-N-hydroxyacetamide with enhanced affinity towards MMP12 catalytic domain to be used as visco-supplement with increased degradation resistance

Leone, Gemma; Pepi, Simone; Consumi, Marco; Lamponi, Stefania; Fragai, Marco; Martinucci, Marco; Baldoneschi, Veronica; Francesconi, Oscar; Nativi, Cristina; Magnani, Agnese

doi:10.1016/j.carbpol.2021.118452

Cited by 6 publications

(7 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HA retention can also be enhanced by functionalizing HA with inhibitors for hyaluronidase and other proteases. For instance, HA covalently modified with a small-molecule MMP inhibitor showed better resistance to degradation by hyaluronidase compared with unmodified HA while demonstrating similar viscoelastic properties to those of human synovial fluid [ 50 ].…”

Section: Ha Hydrogels For Joint Lubricationmentioning

confidence: 99%

Engineering Hyaluronic Acid for the Development of New Treatment Strategies for Osteoarthritis

Kim

Guilak

2022

IJMS

View full text Add to dashboard Cite

Osteoarthritis (OA) is a degenerative joint disease that is characterized by inflammation of the joints, degradation of cartilage, and the remodeling of other joint tissues. Due to the absence of disease-modifying drugs for OA, current clinical treatment options are often only effective at slowing down disease progression and focus mainly on pain management. The field of tissue engineering has therefore been focusing on developing strategies that could be used not only to alleviate symptoms of OA but also to regenerate the damaged tissue. Hyaluronic acid (HA), an integral component of both the synovial fluid and articular cartilage, has gained widespread usage in developing hydrogels that deliver cells and biomolecules to the OA joint thanks to its biocompatibility and ability to support cell growth and the chondrogenic differentiation of encapsulated stem cells, providing binding sites for growth factors. Tissue-engineering strategies have further attempted to improve the role of HA as an OA therapeutic by developing diverse modified HA delivery platforms for enhanced joint retention and controlled drug release. This review summarizes recent advances in developing HA-based hydrogels for OA treatment and provides additional insights into how HA-based therapeutics could be further improved to maximize their potential as a viable treatment option for OA.

show abstract

Section: Ha Hydrogels For Joint Lubricationmentioning

confidence: 99%

Engineering Hyaluronic Acid for the Development of New Treatment Strategies for Osteoarthritis

Kim

Guilak

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The chemical composition, the rheological properties, the nontoxicity, as well as the inhibition properties vs MMPs and the increased enzymatic stability in vitro of the new material with respect to the native hyaluronan has been proved by physicochemical tests, as previously reported. 28 The ability of HA-3 to prevent dehydration of human corneal epithelial cells was first investigated by an in vitro test and compared to a commercial product (OPTO yal A − Sooft Italia S.p.A.). As shown in Figure 2, the treatment of HCECs (human corneal epithelial cells) with the commercial tear substitute (OPTO yal A) and the HA-3 derivative reduces the viability of cells after exposure of the cell monolayer to 30 min of continuous air flow compared to untreated cells (complete medium), but to a significantly lesser extent than with PBS.…”

mentioning

confidence: 99%

“…Inhibitor 3 was efficiently synthesized 27 (see SI) and properly armed to be linked to hyaluronic acid (see SI). 28 Since DES is characterized by an ocular overexpression of MMP-9, the inhibition property of 3 vs MMP-9 (K i = 16.4 ± 1.7 nM) was assessed by an enzymatic assay (see SI for details). We also evaluated the interaction of inhibitor 3 with the catalytic domain of MMP-12 (selected as model MMP) by NMR (Figure S1, Supporting Information).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Functionalized Hyaluronic Acid for “In Situ” Matrix Metalloproteinase Inhibition: A Bioactive Material to Treat the Dry Eye Sydrome

et al. 2022

Self Cite

View full text Add to dashboard Cite

Hyaluronic acid (HA) is a naturally occurring polysaccharide with many molecular functions, including maintaining the structure and physiology of the tissues, tissue remodeling, and inflammation. HA is found naturally in physiological tear fluid, possesses excellent mucus-layer-adhesive properties, and is successfully employed in the treatment of dry eye syndrome (DES). However, HA has as major drawback: its rapid in vivo degradation by hyaluronidase. We report on a unique material, namely, HA-3, obtained by the functionalization of HA with the metalloproteinase inhibitor 3 (MMPI). This material is characterized by an increased resistance to hyaluronidase degradation, associated with MMP inhibition properties. The ability of HA-3 to prevent dehydration of human corneal epithelial cells in vitro and in vivo may accelerate the development of more efficient DES treatment and broaden the application of HA in human diseases.

show abstract

Effect of oxidation state and chelating agent on iron bio-accessibility from different commercial iron-supplements

Pepi,

Talarico,

Leone

et al. 2024

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Sodium hyaluronate-g-2-((N-(6-aminohexyl)-4-methoxyphenyl)sulfonamido)-N-hydroxyacetamide with enhanced affinity towards MMP12 catalytic domain to be used as visco-supplement with increased degradation resistance

Cited by 6 publications

References 54 publications

Engineering Hyaluronic Acid for the Development of New Treatment Strategies for Osteoarthritis

Engineering Hyaluronic Acid for the Development of New Treatment Strategies for Osteoarthritis

Functionalized Hyaluronic Acid for “In Situ” Matrix Metalloproteinase Inhibition: A Bioactive Material to Treat the Dry Eye Sydrome

Effect of oxidation state and chelating agent on iron bio-accessibility from different commercial iron-supplements

Contact Info

Product

Resources

About